What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Cancer
- Gene
His primary areas of investigation include Internal medicine, Multiple myeloma, Gastroenterology, Pathology and Surgery.
His Internal medicine research is multidisciplinary, incorporating elements of Immunology and Oncology.
His Immunology study incorporates themes from Molecular biology and Single-nucleotide polymorphism.
His Multiple myeloma study combines topics in areas such as Monoclonal gammopathy of undetermined significance, Clinical trial, Zoledronic acid, Bone disease and Flow cytometry.
His study in Gastroenterology is interdisciplinary in nature, drawing from both Chromosome 13, Aneuploidy, Melphalan, Dexamethasone and Bence Jones protein.
His work deals with themes such as Leukemia and Immunophenotyping, Antigen, which intersect with Pathology.
His most cited work include:
- Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. (2431 citations)
- Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial (382 citations)
- Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study (356 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Multiple myeloma, Oncology, Immunology and Pathology are his primary areas of study.
His Internal medicine study incorporates themes from Gastroenterology and Surgery.
His study in Multiple myeloma is interdisciplinary in nature, drawing from both Monoclonal gammopathy of undetermined significance, Cancer research and Bone marrow, Minimal residual disease.
His research in Oncology intersects with topics in Waldenstrom macroglobulinemia, Clinical trial, Bioinformatics and Disease.
His Immunology research includes elements of Molecular biology and Stem cell.
He interconnects Flow cytometry and Immunophenotyping in the investigation of issues within Pathology.
He most often published in these fields:
- Internal medicine (53.00%)
- Multiple myeloma (48.50%)
- Oncology (29.50%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (53.00%)
- Oncology (29.50%)
- Multiple myeloma (48.50%)
In recent papers he was focusing on the following fields of study:
Ramón García-Sanz mainly investigates Internal medicine, Oncology, Multiple myeloma, Transplantation and In patient.
His study in Gastroenterology extends to Internal medicine with its themes.
His research integrates issues of Pembrolizumab, Philadelphia Chromosome Positive, Phases of clinical research, Bortezomib and Hazard ratio in his study of Oncology.
His Bortezomib research is multidisciplinary, incorporating perspectives in Denosumab and Zoledronic acid.
His Multiple myeloma study combines topics in areas such as Single-nucleotide polymorphism and Bone marrow, Minimal residual disease.
His biological study spans a wide range of topics, including Refractory Hodgkin Lymphoma, Discontinuation and Pathogenesis.
Between 2018 and 2021, his most popular works were:
- International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders (91 citations)
- Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study (55 citations)
- Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma (44 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
Ramón García-Sanz focuses on Internal medicine, Oncology, Multiple myeloma, Transplantation and Minimal residual disease.
He combines subjects such as Pembrolizumab, Clinical endpoint, Refractory Hodgkin Lymphoma and Treatment efficacy with his study of Oncology.
His studies in Multiple myeloma integrate themes in fields like Clinical trial, Proportional hazards model, Disease, Bone disease and Bone marrow.
His Bone disease study combines topics from a wide range of disciplines, such as Surgery, Radiation therapy and Discontinuation.
The Transplantation study which covers Lenalidomide that intersects with Bortezomib and Thalidomide.
Ramón García-Sanz has included themes like Multiplex polymerase chain reaction, Gene rearrangement, Lymphoid neoplasms, Radiology and DNA sequencing in his Minimal residual disease study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
